Search

Search Results

• Opioid titration with sustained-release oxycodone and immediate-release morphine for moderate/severe cancer pain: A pilot assessment of the CoDem protocol

  Boaz Gedaliahu Samolsky Dekel, MD, PhD, MA, Marco Tomasi, MD, Alessio Vasarri, MD, Alberto Gori, MD, Marco Adversi, MD, Anna Castagnoli, MD, GianFranco Di Nino, MD, Rita Maria Melotti, MD

  29-38

  01/01/2014

• Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency

  Gary Eichenbaum, PhD, Karin Göhler, MD, Mila Etropolski, MD, Ilona Steigerwald, MD, PhD, Joseph Pergolizzi, MD, Myoung Kim, PhD, MA, Gary Vorsanger, PhD, MD

  211-227

  05/01/2015

• A retrospective analysis of the impact of Michigan's opioid prescribing legislation on discharge opioid prescribing at a single institution

  Richard Sadowski, MD, FHM, Emily Hillaker, DO, Michael Chavarria, MD, Fareea Khaliq, MD, Adam Schwark, MD

  467-474

  09/01/2022

• Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): Case report and the focused review of the literature

  Xiulu Ruan, MD, Tao Chen, MD, PhD, Jeff Gudin, MD, John Patrick Couch, MD, Srinivas Chiravuri, MD

  300-303

  01/29/2018

• Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination (MoxDuo®) in the treatment of postoperative pain

  Patricia Richards, MD, PhD, Dennis Riff, MD, Robin Kelen, RN, Warren Stern, PhD

  217-228

  01/15/2018

• Epidemiology of opioid pharmacy claims in the United States

  Rachel E. Williams, PhD, MS, Timothy J. Sampson, BS, Linda Kalilani, MBBS, PhD, John I. Wurzelmann, MD, MPH, Stephen W. Janning, PharmD

  145-152

  01/30/2018

• Retrospective study of the effect of opioid prescribing guidelines on prescribing practices in pediatric orthopedic sports medicine patients having knee surgery: A single institution's experience

  Jeffrey G. Stepan, MD, MSc, Christine Goodbody, MD, Kanupriya Kumar, MD, Kathryn DelPizzo, MD, Peter Fabricant, MD, MPH, Pamela Wendel, MD

  284-288

  07/01/2021

• Do abuse deterrent opioid formulations work?

  Richard C. Dart, MD, PhD, Janetta L. Iwanicki, MD, Nabarun Dasgupta, PhD, Theodore J. Cicero, PhD, Sidney H. Schnoll, MD, PhD

  365-378

  12/07/2017

• Opioid prescribing patterns by drug type: The Pennsylvania experience

  Brock K. Bakewell, MPH, Chaim Miller, BS, Matthew Sherman, BS, Asif M. Ilyas, MD, MBA

  149-156

  03/01/2023

• Self-reports of prescription opioid abuse and diversion among recreational opioid users in a Canadian and a United States city

  Beatrice Setnik, PhD, Carl L. Roland, PharmD, MS, Veeraindar Goli, MD, Glenn C. Pixton, MS, Naama Levy-Cooperman, PhD, Ira Smith, MD, Lynn Webster, MD

  463-473

  11/01/2015

• The ACTION study: A randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA®) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin®) for the treatment of chronic, moderate to severe low back pain

  Richard L. Rauck, MD, Stephen A. Bookbinder, MD, Timothy R. Bunker, MD, Christopher D. Alftine, MD, Richard Ghalie, MD, Andres Negro-Vilar, MD, PhD, Egbert de Jong, MD, Steven Gershon, MD

  155-166

  05/01/2006

• Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use

  Srinivas Nalamachu, MD, Jeffrey Gudin, MD, Catherine Datto, MD, MS, Karin Coyne, PhD, MPH, Jiat-Ling Poon, PhD, Yiqun Hu, MD, PhD

  211-221

  07/02/2018

• Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users

  Kerri A. Schoedel, PhD, Stephen McMorn, PhD, Bijan Chakraborty, MStat, Susan L. Potts, MS, Kathleen Zerbe, RN, Edward M. Sellers, MD, PhD

  179-192

  01/15/2018
• 

  Buprenorphine: Opioid Agonist-Antagonist for Refractory Pain of Sickle Cell Disease Patients During Hematopoietic Stem Cell Transplant, Uncontrolled By Full-Agonist Opioids

  Mayuko Sakae, MD

  B14

  09/19/2024

• In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone

  D. Lynn Kirkpatrick, PhD, William K. Schmidt, PhD, Ricardo Morales, BSc, John Cremin, PhD, Julie Seroogy, BSc, Craig Husfeld, PhD, Thomas Jenkins, PhD

  39-49

  01/01/2017

• Quantification of oxycodone and morphine analytes in urine: Assessment of adherence

  Michael E. M. Larson, PhD, Richard L. Berg, MS, Joyce Flanagan, PhD

  489-500

  11/01/2015

• Oxymorphone and oxymorphone extended release: A pharmacotherapeutic review

  Paul Alexander Sloan, MD, Robert L. Barkin, PharmD, MBA

  131-144

  01/30/2018

• Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs

  Alan G. White, PhD, Joseph LeCates, PhD, Howard G. Birnbaum, PhD, Wendy Cheng, MPH, MPhil, Carl L. Roland, PharmD, MS, Jack Mardekian, PhD

  199-210

  05/01/2015

• Assessment of the use of oral fluid as a matrix for drug monitoring in patients undergoing treatment for opioid addiction

  Frank Kunkel, MD, Elizabeth Fey, MS, Damon Borg, PhD, Richard Stripp, PhD, Christine Getto, BS

  434-442

  09/01/2015

• Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia

  Dana Tarcatu, MD, Cristina Tamasdan, MD, Natalie Moryl, MD, Eugenie Obbens, MD, PhD

  167-170

  05/01/2007